Russian Journal of Skin and Venereal DiseasesRussian Journal of Skin and Venereal DiseasesРоссийский журнал кожных и венерических болезней1560-95882412-9097Eco-Vector3691810.17816/dv36918ArticlesСтатьиResearch ArticleModern aspects of topical therapy in vitiligoСовременные аспекты топической терапии витилигоSharafutdinovaL. AШарафутдиноваЛюция Анваровна

Кафедра кожных и венерических болезней лечебного факультета; аспирант

LomonosovKonstantin M.ЛомоносовКонстантин Михайлович

MD, PhD, DSc, prof.

Кафедра кожных и венерических болезней лечебного факультета; доктор мед. наук, профессор

lamdinic@yandex.ruI.M. Setchenov First Moscow Medical UniversityГБОУ ВПО Первый МГМУ им. И.М. Сеченова Минздрава России15102014175VOL 17, NO5 (2014)ТОМ 17, №5 (2014)404521072020Copyright ©; 2014, Eco-VectorCopyright ©; 2014, ООО "Эко-Вектор"2014Eco-VectorООО "Эко-Вектор"https://rjsvd.com/1560-9588/article/view/36918

Modern topical drug therapies in vitiligo are discussed, with due consideration for the size and location of depigmented foci, activity of the process, clinical variety, presence of concomitant diseases, and age. The most rational modern drugs are topical corticosteroids, topical immunomodulators, topical antioxidants, calcipotriol, liposomal preparation, and prostaglandin E, each of them focused on several pathologically modified components in vitiligo. Intralesional drug injections are maximally effective and promote the onset of a rapid lasting effect with lesser probability of systemic side effects.

Рассмотрены современные разнообразные методы использования топических лекарственных средств в лечении витилиго в зависимости от размеров и локализации депигментированных очагов, степени активности патологического процесса, клинической разновидности, наличия сопутствующей патологии и возрастных особенностей. К наиболее современным и рациональным методам относится применение топических кортикостероидов, топических иммуномодуляторов, топических антиоксидантов, кальципотриола, липосомного препарата, препаратов простагландина Е 2, каждый из которых воздействует на несколько патологически измененных звеньев при витилиго. Описаны внутриочаговые инъекции препаратов, не только обеспечивающие максимальную терапевтическую эффективность, но и способствующие быстрому наступлению и продолжительного эффекта с меньшей вероятностью развития системных побочных эффектов.

vitiligoantioxidantsprostaglandin analogsdiphenylcycloproperonecalcitriolintrafocal injectionstopical corticosteroidsimmunomodulatorsвитилиготопические кортикостероидыиммуномодуляторыантиоксидантыаналоги простагландинадифенилциклопроперонкальципотриолвнутриочаговые инъекцииTaieb A., Picardo M. Epidemiology, definitions and classification. In: Picardo M., Taieb A., eds. Vitiligo. Heidelberg: Springer Verlag; 2010: 13-24.Picardo M., Taieb A. Pathophysiology. Overview. In: Picardo M., Taieb A., eds. Vitiligo. Heidelberg: Springer Verlag; 2010: 149-52.Shajil E.M., Chatterjee S., Agrawal D., Bagchi T., Begum R. Vitiligo: pathomechanisms and genetic polymorphism of susceptible genes. Indian J. Exp. Biol. 2006; 44(7): 526-39.Hossani-Madani A.R., Halder R.M. Topical treatment and combination approaches for vitiligo: new insights, new developments. G. Ital. Dermatol. Venereol. 2010; 145(1): 57-78.Garg B.J., Saraswat A., Bhatia A., Katare O.P. Topical treatment in vitiligo and the potential uses of new drug delivery systems. Indian J. Dermatol. Venereol. Leprol. 2010; 76(3): 231-8. doi: 10.4103/0378-6323.62961.Koga M. Vitiligo: a new classification and therapy. Br. J. Dermatol. 1977; 97(3): 255-61.Khalid M., Mujtaba G. Response of segmental vitiligo to 0.05% clobetasol propionate cream. Int. J. Dermatol. 1998; 37(9): 705-8.Kumari J. Vitiligo treated with topical clobetasol propionate. Arch. Dermatol. 1984; 120(5): 631-5.Kwon H.B., Choi Y., Kim H.J., Lee A.Y. The therapeutic effects of a topical tretinoin and corticosteroid combination for vitiligo: a placebo-controlled, paired-comparison, left-right study. J. Drugs Dermatol. 2013; 12(4): e63-7.Caridi C., Sohn A., Rita V. Patel. Topical сalcineurin inhibitors in the treatment of vitiligo. In: Park К., Murase J., eds. Vitiligo - management and therapy. New York: InTech; 2011: 136.Silverberg J.I., Silverberg N.B. Topical tacrolimus is more effective for treatment of vitiligo in patients of skin of color. J. Drugs Dermatol. 2011; 10(5): 507-10.Udompataikul M., Boonsupthip P., Siriwattanagate R. Effectiveness of 0.1% topical tacrolimus in adult and children patients with vitiligo. J. Dermatol. 2011; 38(6): 536-40. doi: 10.1111/j.1346-8138.2010.01067.x.Sendur N., Karaman G., Sanif N., Savk E. Topical pimecrolimus: a new horizon for vitiligo treatment? J. Dermatol. Treat. 2006; 17(6): 338-42.Kathuria S., Khaitan B.K., Ramam M., Sharma V.K. Segmental vitiligo: A randomized controlled trial to evaluate efficacy and safety of 0.1% tacrolimus ointment vs 0.05% fluticasone propionate cream. Indian J. Dermatol. Venereol. Leprol. 2012; 78(1): 68-73. doi: 10.4103/0378-6323.90949.Passeron T., Ostovari N., Zakaria W., Fontas E., Larrouy J.C., Lacour J.P., et al. Topical tacrolimus and the 308 nm excimer laser: a synergistic combination for the treatment of vitiligo. Arch. Dermatol. 2004; 140(9): 1065-9.Kawalek A.Z., Spencer J.M., Phelps R.G. Combined excimer laser and topical tacrolimus for the treatment of vitiligo: a pilot study. Dermatol. Surg. 2004; 30(2, Pt 1): 130-5.Esfandiarpour I., Ekhlasi A., Farajzadeh S., Shamsadini S. The efficacy of pimecrolimus 1% cream plus narrow-band ultraviolet B in the treatment of vitiligo: a double-blind, placebo-controlled clinical trial. J. Dermatol. Treat. 2009; 20(1): 14-8. doi: 10.1080/09546630802155057.Pires M.C., Martins J.M., Montealegre F., Gatti F.R. Vitiligo after diphencyprone for alopecia areata. Dermatol. Res. Pract. 2010; 2010: 171265. doi: 10.1155/2010/171265.Oh Y.J., Shin M.K., Lee M.H. Narrow-band ultraviolet B treatment for diphenylcyclopropenone-induced vitiliginous lesions. Acta Derm. Venereol. 2012; 92(1): 102-3.Schallreuter K.U., Wood J.M., Lemke K.R., Levenig C. Treatment of vitiligo with a topical application of pseudocatalase and calcium in combination with short-term UVB exposure: a case study on 33 patients. Dermatology. 1995; 190(3): 223-9.Naini F.F., Shooshtari A.V., Ebrahimi B., Molaei R. The effect of pseudocatalase/superoxide dismutase in the treatment of vitiligo: a pilot study. J. Res. Pharm. Pract. 2012; 1(2): 77-80.Kostovic K., Pastar Z., Pasic A., Ceovic R. Treatment of vitiligo with narrow-band UVB and topical gel containing catalase and superoxide dismutase. Acta Dermatovenerol. Croat. 2007; 15(1): 10-4.Sanclemente G., Garcia J.J., Zuleta J.J., Diehl C., Correa C., Falabella R. A double-blind, randomized trial of 0.05% betamethasone vs topical catalase/dismutase superoxide in vitiligo. J. Eur. Acad. Dermatol. Venereol. 2008; 22(11): 135964.Саатов Т.С., Умеров О.И., Саатов Б.Т., Арифов С.С. Создание липосомного препарата для лечения витилиго. Вестник новых медицинских технологий. 2012; 1.Kumaran M.S., Kaur I., Kumar B. Effect of topical calcipotriol, betamethasone dipropionate and their combination in the treatment of localized vitiligo. J. Eur. Acad. Dermatol. Venereol. 2006; 20(3): 269-73.Cherif F., Azaiz M.I., Ben Hamida A., Ben O., Dhari A. Calcipotriol and PUVA as treatment for vitiligo. Dermatol. Online J. 2003; 9(5): 4.Goktas E.O., Aydin F., Senturk N., Canturk M.T., Turanli A.Y. Combination of narrow band UVB and topical calcipotriol for the treatment of vitiligo. J. Eur. Acad. Dermatol. Venereol. 2006; 20(5): 553-7.Parsad D., Pandhi R., Dogra S., Kumar B. Topical prostaglandin analog (PGE2) in vitiligo--a preliminary study. Int. J. Dermatol. 2002; 41(12): 942-5.Kapoor R., Phiske M.M., Jerajani H.R. Evaluation of safety and efficacy of topical prostaglandin E2 in treatment of vitiligo. Br. J. Dermatol. 2009; 160(4): 861--3. doi: 10.1111/j.1365-2133.2008.08923.x.Sharpe E.D., Reynolds A.C., Skuta G.L., Jenkins J.N., Stewart W.C. The clinical impact and incidence of periocular pigmentation associated with either latanoprost or bimatoprost therapy. Curr. Eye Res. 2007; 32(12): 1037-43.Kandil E. Treatment of localized vitiligo with intradermal injections of triamcinolone acetonide. Dermatologica. 1970; 140(3): 195-206.Abd El-Samad Z., Shaaban D. Treatment of localized non-segmental vitiligo with intradermal 5-flurouracil injection combined with narrow-band ultraviolet B: a preliminary study. J. Dermatol. Treat. 2012; 23(6): 443-8. doi: 10.3109/09546634.2011.579084.Skurkovich S., Korotky N.G., Sharova N.M., Skurkovich B. Successful anti-IFN-c therapy of alopecia areata, vitiligo, and psoriasis. In: Federation of clinical immunology society (FOCIS): 2nd Annual Meeting. San Francisco, June 28, 2002.Jeon S., Kim N.H., Koo B.S., Lee H.J., Lee A.Y. Bee venom stimulates human melanocyte proliferation, melanogenesis, dendricity and migration. Exp. Mol. Med. 2007; 39(5): 603-13.AlGhamdi K.M., Khurrum H. Pilot trial evaluating the treatment of focal vitiligo with intralesional honeybee venom injection. J. Cutan. Med. Surg. 2012; 16(6): 385-6.